AbbVie Inc. (NYSE:ABBV) Q1 2025 – Earnings Conference Call April 25, 2025 9:00 PM ET
Company Participants
Liz Shea – Senior VP, IR
Rob Michael – CEO
Jeff Stewart – EVP, Chief Commercial Officer
Roopal Thakkar – EVP, R&D, Chief Scientific Officer
Scott Reents – EVP, CFO
Carrie Strom – SVP of AbbVie, and President of Global Allergan Aesthetics
Conference Call Participants
Chris Schott – JPMorgan
Terence Flynn – Morgan Stanley
Carter Gould – Cantor
Courtney Breen – Bernstein
Mohit Bansal – Wells Fargo
Steve Scala – TD Cowen
Dave Risinger – Leerink Partners
Vamil Divan – Guggenheim Securities
Alexandria Hammond – Wolfe Research
James Shin – Deutsche Bank
Geoff Meacham – Citibank
Tim Anderson – Bank of America
Trung Huynh – UBS
Operator
Welcome to the AbbVie First Quarter 2025 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. As a reminder, this call is being recorded. I would now like to introduce Ms. Shea, Senior Vice President, Investor Relations.
Liz Shea
Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chief Executive Officer Jeff Stewart, Executive Vice President, Chief Commercial Officer Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer and Scott Reents, Executive Vice President, Chief Financial Officer.
Before we get started, I’ll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings.
AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today’s conference call, non-GAAP
